Toronto Dominion Bank reduced its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 91.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the exchange traded fund’s stock after selling 504,451 shares during the period. Toronto Dominion Bank owned approximately 0.06% of SPDR S&P Biotech ETF worth $3,811,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of XBI. Northwest Investment Counselors LLC acquired a new position in SPDR S&P Biotech ETF during the 1st quarter worth approximately $27,000. New Hampshire Trust acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth approximately $29,000. J Arnold Wealth Management Co acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth approximately $29,000. Compass Wealth Management LLC purchased a new stake in SPDR S&P Biotech ETF during the 4th quarter worth approximately $34,000. Finally, Fortis Capital Advisors LLC purchased a new stake in SPDR S&P Biotech ETF during the 4th quarter worth approximately $38,000.
SPDR S&P Biotech ETF Stock Up 2.4 %
XBI stock opened at $81.13 on Friday. SPDR S&P Biotech ETF has a 52-week low of $72.44 and a 52-week high of $92.60. The stock’s 50 day moving average is $81.68 and its two-hundred day moving average is $82.07. The company has a market capitalization of $6.22 billion, a PE ratio of 11.47 and a beta of 0.97.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 8/28 – 9/1
- Crypto vs Stocks: How to Choose Your Investments
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- High Flyers: 3 Natural Gas Stocks for March 2022
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.